Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2003, Vol. 8 ›› Issue (4): 393-395.

Previous Articles     Next Articles

Reversal oflomerizine on multidrug resistance in humanleukemia cellline K562 ADM

WU Yu-Lin, ZHU Hao-Jie1, lIU Guo-Qing1   

  1. Department ofPhysiology,ChinaPharmaceutical University,Nanjing 210009,Jiangsu,China;
    1Department ofPharmacology,ChinaPharmaceutical University,Nanjing 210009,Jiangsu,China
  • Received:2003-03-20 Revised:2003-04-01 Online:2003-08-26 Published:2020-11-19

Abstract: AIM: To investigate the efficacy oflomerizine on multidrug resistance(MDR)reversal and its mechanism.METHODS: Cytotoxicity of daunomycin(DNR)on K562/ADM was assessed by MTT assay in thePresence oflomerizine.Fluorescence ofP-glycoprotein(P-gp)substrate rhodamine123(Rh123)in K562/ADM was measured by fluorescence spectrophotometry and flow cytometry.RESULTS: Lomerizine could significantly increase the chemosensitivity of K562/ADM to DNR and intracellular content of Rh123.No effect was found in K562 cells.CONCLUSION: Lomerizine shows significant inhibition on the activity ofP-gPin K562/ADM,increases intracellular accumulation ofP-gPsubstrates,and enhances cytotoxicity of other anticancer drugs.

Key words: pharmacology, lomerizine, P-glycoprotein, P-glycoprotein inhibitor, multidrug resistance

CLC Number: